Sun ZJ, Hu XP, Fan BH, Wang W. Epstein-Barr virus-positive post-transplant lymphoproliferative disordepresenting as hematochezia and enterobrosis in renal transplant recipients in China: A report of two cases. World J Clin Cases 2019; 7(24): 4334-4341 [PMID: 31911916 DOI: 10.12998/wjcc.v7.i24.4334]
Corresponding Author of This Article
Wei Wang, PhD, Chief Doctor, Professor, Surgeon, Institute of Urology, Capital Medical University, Department of Urology, Capital Medical University Beijing Chaoyang Hospital, 7th Floor, Building B, 8 Workers Stadium South Road, Beijing 100030, China. sunzejia1002@sina.com
Research Domain of This Article
Transplantation
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 26, 2019; 7(24): 4334-4341 Published online Dec 26, 2019. doi: 10.12998/wjcc.v7.i24.4334
Epstein-Barr virus-positive post-transplant lymphoproliferative disordepresenting as hematochezia and enterobrosis in renal transplant recipients in China: A report of two cases
Ze-Jia Sun, Xiao-Peng Hu, Bo-Han Fan, Wei Wang
Ze-Jia Sun, Xiao-Peng Hu, Bo-Han Fan, Wei Wang, Institute of Urology, Capital Medical University, Department of Urology, Beijng Chao-Yang Hospital, Capital Medical University, Beijing 100030, China
Author contributions: All of the authors participated in the writing of the article.
Supported bythe National Natural Science Foundation of China, No. 81771720.
Informed consent statement: We obtained the informed consent from the patients.
Conflict-of-interest statement: We declare that there is no conflict of interest related to this report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wei Wang, PhD, Chief Doctor, Professor, Surgeon, Institute of Urology, Capital Medical University, Department of Urology, Capital Medical University Beijing Chaoyang Hospital, 7th Floor, Building B, 8 Workers Stadium South Road, Beijing 100030, China. sunzejia1002@sina.com
Telephone: +86-13910790920
Received: May 10, 2019 Peer-review started: May 14, 2019 First decision: September 9, 2019 Revised: October 22, 2019 Accepted: November 14, 2019 Article in press: November 14, 2019 Published online: December 26, 2019 Processing time: 229 Days and 6.2 Hours
Abstract
BACKGROUND
Post-transplant lymphoproliferative disorder (PTLD) is a rare severe complication after renal transplantation, with an incidence of approximately 0.3%-2.0% in patients undergoing renal transplantation. The clinical manifestations of PTLD are often nonspecific, leading to tremendous challenges in the clinical diagnosis and treatment of PTLD.
CASE SUMMARY
We report two Epstein-Barr virus (EBV)-positive PTLD cases whose main clinical manifestations were digestive tract symptoms. Both of them admitted to our hospital because of extranodal infiltration symptoms and we did not suspect of PTLD until the pathology confirmation. Luckily, they responded well to the treatment of rituximab. We also discuss the virological monitoring, clinical characteristics, diagnosis, and treatment of PTLD.
CONCLUSION
PTLD is a deceptive disease and difficult to diagnose. Once patients are confirmed with PTLD, immune suppressant dosage should be immediately reduced and rituximab should be used as first-line therapy.
Core tip: Post-transplant lymphoproliferative disorder (PTLD) is a rare severe complication after renal transplantation, with an incidence of approximately 0.3%-2.0% in patients undergoing renal transplantation. We report two Epstein-Barr virus-positive PTLD cases whose main clinical manifestations were digestive tract symptoms. As both of them admitted to our hospital because of extranodal infiltration symptoms, we did not suspect of PTLD until the pathology confirmation. We also discuss the virological monitoring, clinical characteristics, diagnosis, and treatment of PTLD.
